It’s NADAC survey results week, which means it’s time for our next installment of “what happened to generic drug prices last month.” We saw a lot of price increases this past month, and an overall decrease in annualized spending, after a couple months of concerning trends. As always, the details matter, and we’re here to provide them for you. Check out our latest drug pricing report for a lot of important updates, plus an updated NADAC Packed Bubble Chart.
As drug pricing scrutiny grows, PBM spread pricing of cheap, generic drugs is becoming a hot topic of conversation in states across the country. After the state of Ohio opened the books thanks to an audit from the state auditor, the uncovered $224 million PBM spread now has other states scrambling to see what they are being charged as well. One of those states is Pennsylvania, where their state auditor is trying hard to get the data he needs to see where the money is going in the third largest managed care program in the country. Since there are many folks wondering what’s going on in Pennsylvania, considering the current lack of hard data, we decided to dig into the publicly available data to see if Pennsylvania appears to have the makings of an “Ohio problem.”